Evidence map›Paper›PMID 40071326›Full record

ArticleCirculation2025

An NRF2/β3-Adrenoreceptor Axis Drives a Sustained Antioxidant and Metabolic Rewiring Through the Pentose-Phosphate Pathway to Alleviate Cardiac Stress.

Lauriane Y M Michel, Hrag Esfahani, Delphine De Mulder, Roxane Verdoy, Jérôme Ambroise, Véronique Roelants, Bertrand Bouchard, Nathalie Fabian, Jérôme Savary, Joseph P Dewulf and 10 more

Abstract read
In one paragraph

Article in Circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lauriane Y M MichelInstitute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St. Luc and Université catholique de Louvain, Brussels, Belgium (L.Y.M.M., H.E., D.d.M., R.V., N.F., J.-L.B.).ORCID 0000-0001-6733-3510
Hrag EsfahaniInstitute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St. Luc and Université catholique de Louvain, Brussels, Belgium (L.Y.M.M., H.E., D.d.M., R.V., N.F., J.-L.B.).
Delphine De MulderInstitute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St. Luc and Université catholique de Louvain, Brussels, Belgium (L.Y.M.M., H.E., D.d.M., R.V., N.F., J.-L.B.).
Roxane VerdoyInstitute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St. Luc and Université catholique de Louvain, Brussels, Belgium (L.Y.M.M., H.E., D.d.M., R.V., N.F., J.-L.B.).
Jérôme AmbroiseInstitute of Experimental and Clinical Research (IREC), Centre des Technologies Moléculaires Appliquées, Université catholique de Louvain, Brussels, Belgium (J.A.).
Véronique RoelantsInstitute of Experimental and Clinical Research (IREC), Molecular imagery, radiotherapy, oncology (MIRO), Cliniques Universitaires St. Luc and Université catholique de Louvain, Brussels, Belgium (V.R., T.D.).ORCID 0000-0003-4278-028X
Bertrand BouchardMontreal Heart Institute Research Center, Quebec, Canada (B.B., M.R., C.D.R.).ORCID 0009-0000-4023-0642
Nathalie FabianInstitute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St. Luc and Université catholique de Louvain, Brussels, Belgium (L.Y.M.M., H.E., D.d.M., R.V., N.F., J.-L.B.).ORCID 0009-0005-9450-8829
Jérôme SavaryInstitute of Condensed Matter and Nanosciences (IMCN), Université catholique de Louvain, Louvain-la-Neuve, Belgium (J.S., M.L.S.).
Joseph P DewulfClinical Chemistry Department, Cliniques universitaires St. Luc and Louvain Centre for Toxicology and Applied Pharmacology, Université catholique de Louvain, Brussels, Belgium (J.P.D., V.H.).ORCID 0000-0001-7223-2706
Thomas DoumontInstitute of Experimental and Clinical Research (IREC), Molecular imagery, radiotherapy, oncology (MIRO), Cliniques Universitaires St. Luc and Université catholique de Louvain, Brussels, Belgium (V.R., T.D.).
Caroline Bouzin2IP-IREC Imaging Platform, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain, RRID:SCR_023378, Brussels, Belgium (C.B.).ORCID 0000-0003-0694-1947
Vincent HaufroidClinical Chemistry Department, Cliniques universitaires St. Luc and Louvain Centre for Toxicology and Applied Pharmacology, Université catholique de Louvain, Brussels, Belgium (J.P.D., V.H.).
Joost J F P LuikenDepartments of Genetics & Cell Biology and Clinical Genetics, Faculty of Health, Medicine and Life Sciences, Maastricht University Medical Center, Maastricht, the Netherlands (J.J.F.P.L., M.N.).ORCID 0000-0002-8808-2631
Miranda NabbenDepartments of Genetics & Cell Biology and Clinical Genetics, Faculty of Health, Medicine and Life Sciences, Maastricht University Medical Center, Maastricht, the Netherlands (J.J.F.P.L., M.N.).ORCID 0000-0002-5691-1634
Michael L SingletonInstitute of Condensed Matter and Nanosciences (IMCN), Université catholique de Louvain, Louvain-la-Neuve, Belgium (J.S., M.L.S.).ORCID 0000-0002-4018-9595
Luc BertrandInstitute of Experimental and Clinical Research (IREC), Pole of Cardiovascular Research (CARD), Université catholique de Louvain, Brussels, Belgium (L.B.).ORCID 0000-0003-0655-7099
Matthieu RuizMontreal Heart Institute Research Center, Quebec, Canada (B.B., M.R., C.D.R.).
Christine Des RosiersMontreal Heart Institute Research Center, Quebec, Canada (B.B., M.R., C.D.R.).
Jean-Luc BalligandInstitute of Experimental and Clinical Research (IREC), Pharmacology and Therapeutics (FATH), Cliniques Universitaires St. Luc and Université catholique de Louvain, Brussels, Belgium (L.Y.M.M., H.E., D.d.M., R.V., N.F., J.-L.B.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiac β3-adrenergic receptors (ARs) are upregulated in diseased hearts and mediate antithetic effects to those of β1AR and β2AR. β3AR agonists were recently shown to protect against myocardial remodeling in preclinical studies and to improve systolic function in patients with severe heart failure. However, the underlying mechanisms remain elusive.

methodsTo dissect functional, transcriptional, and metabolic effects, hearts and isolated ventricular myocytes from mice harboring a moderate, cardiac-specific expression of a human

resultsCompared with wild-type littermates, β3AR-Tg mice were protected from hypertrophy after transaortic constriction, and systolic function was preserved. β3AR-expressing hearts displayed enhanced myocardial glucose uptake under stress in the absence of increased lactate levels. Instead, metabolomic and metabolic flux analyses in stressed hearts revealed an increase in intermediates of the pentose-phosphate pathway in β3AR-Tg, an alternative route of glucose utilization, paralleled with increased transcript levels of NADPH-producing and rate-limiting enzymes of the pentose-phosphate pathway, without fueling the hexosamine metabolism. The ensuing increased content of NADPH and of reduced glutathione decreased myocyte oxidant stress, whereas downstream oxidative metabolism assessed by oxygen consumption was preserved with higher glucose oxidation in β3AR-Tg mice after transaortic constriction compared with wild type, together with increased mitochondrial biogenesis. Unbiased transcriptomics and pathway analysis identified NRF2 (NFE2L2) as an upstream transcription factor that was functionally verified in vivo and in β3AR-expressing cardiac myocytes, where its translocation and nuclear activity were dependent on β3AR activation of nitric oxide synthase and nitric oxide production through S-nitrosation of the NRF2-negative regulator Keap1.

conclusionsModerate expression of cardiac β3AR, at levels observed in human cardiac myocardium, exerts metabolic and antioxidant effects through activation of the pentose-phosphate pathway and NRF2 pathway through S-nitrosation of Keap1, thereby preserving myocardial oxidative metabolism, function, and integrity under pathophysiological stress.

Indexed as

AntioxidantsHeart FailureMyocytes, CardiacNF-E2-Related Factor 2Pentose Phosphate PathwayReceptors, Adrenergic, beta-3AnimalsHumansMaleMiceMice, Inbred C57BLMice, TransgenicOxidative StressRatsSignal TransductionAntioxidantsNfe2l2 protein, mouseNF-E2-Related Factor 2Receptors, Adrenergic, beta-3hypertrophymetabolismmyocytes, cardiacoxidantspentose phosphate pathwayreceptors, adrenergic, beta-3

Identifiers

PMID40071326
PMCPMC12052078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.